Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians

References

1. 1.↵
   1. Greendale GA,
   2. Lee NP,
   3. Arriola ER

   . The menopause. Lancet 1999;353:571–80.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Santen RJ,
   2. Allred DC,
   3. Ardoin SP,
   4. et al

   . Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1–s66.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Hulley S,
   2. Grady D,
   3. Bush T,
   4. et al

   . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Viscoli CM,
   2. Brass LM,
   3. Kernan WN,
   4. Sarrel PM,
   5. Suissa S,
   6. Horwitz RI

   . A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243–9.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Rossouw JE,
   2. Anderson GL,
   3. Prentice RL,
   4. et al

   . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   ACOG Committee of Gynecologic Practice. Committee opinion #322: compounded bioidentical hormones Obstet Gynecol 2005;106(5 Pt 1):1139–40.
8. 8.↵
   1. Taylor M

   . Unconventional estrogens: estriol, biest, and triest. Clin Obstet Gynecol 2001;44:864–79.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Lethaby AE,
   2. Brown J,
   3. Marjoribanks J,
   4. Kronenberg F,
   5. Roberts H,
   6. Eden J

   . Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395.
10. 10.↵
    1. Utian WH,
    2. Archer DF,
    3. Bachmann GA,
    4. et al

    . Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–602.

    OpenUrlPubMedWeb of Science
11. 11.↵
    US Department of Health & Human Services, Food and Drug Administration. For consumers. Bio-identicals: sorting myths from facts. Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049311.htm. Accessed January 18, 2011.
12. 12.↵
    The North American Menopause Society. Hormone products for postmenopausal use in the United States and Canada. Available from: http://www.menopause.org/htcharts.pdf. Accessed January 18, 2011.
13. 13.↵
    US Department of Health & Human Services, Food and Drug Administration. Importation of active pharmaceutical ingredients (APIs) requirements CPG 460.200 pharmacy compounding compliance policy guides manual (tab M). Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM118050.pdf. Accessed January 18, 2011.
14. 14.↵
    US Pharmacopeial Convention, Council of the Convention Section on the Quality of Compounded Medicine. White paper: a model system to promote access to good quality compounded medicines. Available from: http://www.usp.org/pdf/EN/members/goodMedicine.pdf. Accessed January 18, 2011.
15. 15.↵
    US Pharmacopeial Convention, Council of the Convention Section on the Quality of Compounded Medicine. White paper: USP's role in setting enforceable quality standards for medicines. Available from: http://www.usp.org/pdf/EN/members/qualityMedicines.pdf. Accessed January 18, 2011.
16. 16.↵
    Food and Drug Administration Office of Women's Health. FDA takes action against compounded menopause hormone therapy drugs. Available from: http://orwh.od.nih.gov/FDA_ActionHormoneTherapyDrugs.html. Accessed June 25, 2009.
17. 17.↵
    1. Chervenak J

    . Bioidentical hormones for maturing women. Maturitas 2009;64:86–9.

    OpenUrlPubMed
18. 18.↵
    US Department of Health & Human Services, Food and Drug Administration. Compounded menopausal hormone therapy questions and answers. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm183088.htm. Accessed January 18, 2011.
19. 19.↵
    1. Boothby LA,
    2. Doering PL,
    3. Kipersztok S

    . Bioidentical hormone therapy: a review. Menopause 2004;11:356–67.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Vining RF,
    2. McGinley RA,
    3. Symons RG

    . Hormones in saliva: mode of entry and consequent implications for clinical interpretation. Clin Chem 1983;29:1752–6.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    US Department of Health & Human Services, Food and Drug Administration. Transcript of FDA press conference on FDA actions on bio-identical hormones. Available from: http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucm122174.pdf. Accessed January 18, 2011.
22. 22.↵
    1. Kuiper GG,
    2. Carlsson B,
    3. Grandien K,
    4. et al

    . Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863–70.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Eckler K

    . Are all estrogens created equal? Menopause 2004;11:7–8.

    OpenUrlPubMed
24. 24.↵
    1. Eden JA,
    2. Hacker NF,
    3. Fortune M

    . Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust 2007;187:244–5.

    OpenUrlPubMed
25. 25.↵
    1. Fitzpatrick LA,
    2. Good A

    . Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 1999;72:389–97.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Barrett-Connor E,
    2. Slone S,
    3. Greendale G,
    4. et al

    . The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997;27:261–74.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Montplaisir J,
    2. Lorrain J,
    3. Denesle R,
    4. Petit D

    . Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001;8:10–6.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. de Lignieres B

    . Oral micronized progesterone. Clin Ther 1999;21:41–60, discussion 1–2.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Sitruk-Ware R,
    2. Bricaire C,
    3. De Lignieres B,
    4. Yaneva H,
    5. Mauvais-Jarvis P

    . Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications–a review. Contraception 1987;36:373–402.

    OpenUrlPubMed
30. 30.↵
    1. Anderson GL,
    2. Limacher M,
    3. Assaf AR,
    4. et al

    . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Fournier A,
    2. Berrino F,
    3. Clavel-Chapelon F

    . Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Lewis JG,
    2. McGill H,
    3. Patton VM,
    4. Elder PA

    . Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2002;41:1–6.

    OpenUrlPubMed
33. 33.↵
    1. Kocis P

    . Prasterone. Am J Health Syst Pharm 2006;63:2201–10.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Panjari M,
    2. Davis SR

    . DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239–48.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Stomati M,
    2. Monteleone P,
    3. Casarosa E,
    4. et al

    . Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14:342–63.

    OpenUrlPubMedWeb of Science
36. 36.↵
    1. Kritz-Silverstein D,
    2. von Muhlen D,
    3. Laughlin GA,
    4. Bettencourt R

    . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc 2008;56:1292–8.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.↵
    1. Raven PW,
    2. Hinson JP

    . Dehydroepiandrosterone (DHEA) and the menopause: an update. Menopause Int 2007;13:75–8.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Kaaks R,
    2. Rinaldi S,
    3. Key TJ,
    4. et al

    . Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071–82.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Bachmann G,
    2. Bancroft J,
    3. Braunstein G,
    4. et al

    . Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002;77:660–5.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Wierman ME,
    2. Basson R,
    3. Davis SR,
    4. et al

    . Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697–710.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Somboonporn W,
    2. Davis S,
    3. Seif MW,
    4. Bell R

    . Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;(4):CD004509.
42. 42.↵
    1. Bachmann GA

    . The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 2002;77(Suppl 4):S72–6.

    OpenUrlCrossRefPubMed
43. 43.↵
    North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005;12:496–511; quiz 649.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Davis SR,
    2. McCloud P,
    3. Strauss BJ,
    4. Burger H

    . Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227–36.

    OpenUrlCrossRefPubMedWeb of Science
45. 45.↵
    1. Sherwin BB

    . Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord 1988;14:177–87.

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    1. Shifren JL,
    2. Braunstein GD,
    3. Simon JA,
    4. et al

    . Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–8.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    1. Shufelt CL,
    2. Braunstein GD

    . Safety of testosterone use in women. Maturitas 2009;63:63–6.

    OpenUrlPubMed
48. 48.↵
    1. Nippoldt TB

    Mayo Clinic. Addison's disease. Is there such a thing as adrenal fatigue? Available from: http://www.mayoclinic.com/health/adrenal-fatigue/AN01583. Accessed January 18, 2011.